These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7977518)

  • 1. Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer.
    Monk BJ; Chapman JA; Johnson GA; Brightman BK; Wilczynski SP; Schell MJ; Fan H
    Am J Obstet Gynecol; 1994 Nov; 171(5):1193-8. PubMed ID: 7977518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
    Buchynska LG; Brieieva OV; Iurchenko NP
    Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene alterations in endometrial carcinoma.
    Borst MP; Baker VV; Dixon D; Hatch KD; Shingleton HM; Miller DM
    Gynecol Oncol; 1990 Sep; 38(3):364-6. PubMed ID: 2227549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma.
    Chung TK; Cheung TH; To KF; Wong YF
    Gynecol Obstet Invest; 2000; 49(1):47-51. PubMed ID: 10629373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma.
    Beckhardt RN; Kiyokawa N; Xi L; Liu TJ; Hung MC; el-Naggar AK; Zhang HZ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1265-70. PubMed ID: 7576473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
    Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
    Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL; Borelli KA; Hsu PH
    Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
    Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
    Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
    Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
    Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.
    Esteller M; García A; Martínez i Palones JM; Cabero A; Reventós J
    Cancer; 1995 Apr; 75(8):2139-46. PubMed ID: 7697605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
    Bland AE; Stone R; Heuser C; Shu J; Jazaeri A; Shutter J; Atkins K; Rice L
    Int J Gynecol Cancer; 2009 Feb; 19(2):261-5. PubMed ID: 19396006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
    Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site.
    Albino AP; Jaehne J; Altorki N; Blundell M; Urmacher C; Lauwers G; Niedzwiecki D; Kelsen DP
    Eur J Surg Oncol; 1995 Feb; 21(1):56-60. PubMed ID: 7851555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer.
    Bolufer P; Molina R; Ruiz A; Hernandez M; Vazquez C; Lluch A
    Clin Chim Acta; 1994 Sep; 229(1-2):107-22. PubMed ID: 7988041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular biological study on the overexpression of c-myc gene in uterine cervical carcinomas].
    Tanimoto H; Nagai N; Fujimoto H; Ohta S; Ohama K
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):566-70. PubMed ID: 1619315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
    Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
    Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.